<i>Bmpr1aa</i> modulates the severity of the skeletal phenotype in an <i>fkbp10</i>-deficient Bruck syndrome zebrafish model
Rare monogenic disorders often exhibit significant phenotypic variability among individuals sharing identical genetic mutations. Bruck syndrome (BS), a prime example, is characterized by bone fragility and congenital contractures, although with a pronounced variability among family members. BS arises from recessive biallelic mutations in FKBP10 or PLOD2. FKBP65, the protein encoded by FKBP10, collaborates with the LH2 enzyme (PLOD2) in type I collagen telopeptide lysine hydroxylation, crucial for collagen cross-linking. To identify potential modifier genes and to investigate the mechanistic role of FKBP10 in BS pathogenesis, we established an fkbp10a knockout zebrafish model. Mass-spectrometry analysis in fkbp10a-/- mutants revealed a generally decreased type I collagen lysyl hydroxylation, paralleled by a wide skeletal variability similar to human patients. Ultrastructural examination of the skeleton in severely affected mutants showed enlarged type I collagen fibrils and disturbed elastin layers. Whole-exome sequencing of 7 mildly and 7 severely affected mutant zebrafish siblings, followed by single nucleotide polymorphism-based linkage analysis, indicated a linked region on chromosome 13, which segregates with phenotypic severity. Transcriptome analysis identified 6 differentially expressed genes (DEGs) between mildly and severely affected mutants. The convergence of genes within the linked region and DEGs highlighted bmpr1aa as a potential modifier gene, as its reduced expression correlates with increased skeletal severity. In summary, our study provides deeper insights into the role of FKBP10 in BS pathogenesis. Additionally, we identified a pivotal gene that influences phenotypic severity in a zebrafish model of BS. These findings hold promise for novel treatments in the field of bone diseases.
Authors
- Mauro Milazzo (ORCID: https://orcid.org/0009-0002-4861-7133)
- Matthieu Boone (ORCID: https://orcid.org/0000-0002-5478-4141)
- Iván Josipovic (ORCID: https://orcid.org/0000-0002-3349-4698)
- Toon Rosseel (ORCID: https://orcid.org/0000-0002-8155-3197)
- Hanna De Saffel
- P. Eckhard Witten (ORCID: https://orcid.org/0000-0002-2928-5762)
- Tamara Jarayseh (ORCID: https://orcid.org/0000-0002-7403-4938)
- Paul Coucke (ORCID: https://orcid.org/0000-0001-7119-586X)
- Andy Willaert (ORCID: https://orcid.org/0000-0002-9543-1932)
- Sophie Debaenst (ORCID: https://orcid.org/0000-0001-7598-919X)
- Yannick Gansemans (ORCID: https://orcid.org/0000-0001-5018-044X)
- Filip Van Nieuwerburgh (ORCID: https://orcid.org/0000-0001-8815-5485)
- Jan Willem Bek (ORCID: https://orcid.org/0000-0003-1337-1970)
- David M. Hudson (ORCID: https://orcid.org/0000-0002-3253-9890)
Institutions
- HOGENT University of Applied Sciences and Arts (BE)
- University of Washington (US)
- Ghent University Hospital (BE)
- Ghent University (BE)
- Pharmaceutical Biotechnology (Czechia) (CZ)
- Seattle University (US)
Publication Details
- Journal
- Journal of Bone and Mineral Research
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/jbmr/zjae185
- Citations
- 4
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Universiteit Gent